Literature DB >> 17916132

Activity of Nidus Vespae extract and chemical fractions against Streptococcus mutans biofilms.

J Xiao1, X D Zhou, J Feng, Y Q Hao, J Y Li.   

Abstract

AIMS: To evaluate the effect of Nidus Vespae extract and chemical fractions on the viability and architecture of Streptococcus mutans biofilms. METHODS AND
RESULTS: The raw material was first extracted using 95% ethanol/water. Subsequent fractions were prepared from this extract using cyclohexane/ethyl acetate, petroleum ether/ethyl acetate and chloroform/methanol. The biomass dry weight and total protein of samples treated with Nidus Vespae extract and chemical fractions were significantly less than those treated with the vehicle control (P < 0.05). Biofilms treated with Nidus Vespae also resulted in lower percentage of polysaccharide composition. The pH decrease in the biofilm matrix was retarded by Nidus Vespae compared with the vehicle control. Architecture of biofilms treated with Nidus Vespae was different than in the vehicle control and 0.05% chlorhexidine.
CONCLUSIONS: Chloroform/methanol fraction was the most effective treatment. SIGNIFICANCE AND IMPACT OF THE STUDY: The significant antibiofilm activity demonstrated by Nidus Vespae shows it to be a promising source of novel anticariogenic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916132     DOI: 10.1111/j.1472-765X.2007.02230.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  2 in total

1.  The Immunomodulatory Effects of Nidus Vespae on Human Peripheral Blood Immune Cells In Vitro.

Authors:  Ming Zhu; Yang Ling; Qiufeng Qi; Yaping Zhang; Yanqing Bao; Yongping Liu
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-03       Impact factor: 2.629

2.  Inhibitory Effect of Dodonaea viscosa var. angustifolia on the Virulence Properties of the Oral Pathogens Streptococcus mutans and Porphyromonas gingivalis.

Authors:  Mrudula Patel; Roxanne Naidoo; Foluso John Owotade
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-07       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.